Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 461 drug-target rows in SSL view, for TSG = TCF3.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
sunitinib TCF3 KIT 5
crizotinib TCF3 ALK 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab TCF3 KIT 3
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab TCF3 RET 3
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab TCF3 ABL1 3
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) TCF3 KIT 3
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) TCF3 RET 3
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) TCF3 ABL1 3
regorafenib TCF3 KIT 5
regorafenib TCF3 RET 5
regorafenib TCF3 ABL1 5
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TCF3 ALK 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TCF3 KIT 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TCF3 MAP2K2 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TCF3 RET 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TCF3 ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TCF3 ALK 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TCF3 MAP2K2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TCF3 RET 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TCF3 ABL1 2
alectinib, stereotactic radiosurgery TCF3 ALK 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib TCF3 MAP2K2 2
cabozantinib TCF3 RET 2
cft1946, trametinib, cetuximab TCF3 MAP2K2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib TCF3 ALK 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib TCF3 RET 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib TCF3 MAP2K2 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate TCF3 KIT 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate TCF3 RET 2
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells TCF3 CHRNB4 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a TCF3 KIT 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a TCF3 RET 2
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone TCF3 RXRB 2
pembrolizumab, belzutifan, lenvatinib TCF3 KIT 2
pembrolizumab, belzutifan, lenvatinib TCF3 RET 2
pembrolizumab, guadecitabine, mocetinostat TCF3 HDAC3 2
pembrolizumab, lenvatinib TCF3 KIT 2
pembrolizumab, lenvatinib TCF3 RET 2
pharmacological study, romidepsin TCF3 HDAC4 2
pharmacological study, romidepsin TCF3 ABCC1 2
regorafenib, laboratory biomarker analysis TCF3 KIT 2
regorafenib, laboratory biomarker analysis TCF3 RET 2
regorafenib, laboratory biomarker analysis TCF3 ABL1 2
selumetinib, medi4736, tremelimumab TCF3 MAP2K2 2
avapritinib TCF3 KIT 5
binimetinib TCF3 MAP2K2 5
bosutinib TCF3 ABL1 5
carfilzomib TCF3 PSMB5 5
pazopanib TCF3 KIT 5
ponatinib TCF3 ABL1 5
selpercatinib TCF3 RET 5
sorafenib TCF3 KIT 5
sorafenib TCF3 RET 5
vandetanib TCF3 RET 5
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat TCF3 HDAC3 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat TCF3 HDAC3 1
acetazolamide, temozolomide TCF3 CA3 1
acetazolamide, temozolomide TCF3 CA14 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TCF3 KIT 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TCF3 ABL1 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib TCF3 MAP2K2 1
alvocidib, docetaxel TCF3 CDK9 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis TCF3 CDK9 1
alvocidib, paclitaxel TCF3 CDK9 1
aminolevulinic acid TCF3 ALAD 1
aminolevulinic acid, surgical resection TCF3 ALAD 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib TCF3 ALK 1
arsenic trioxide TCF3 IKBKB 1
arsenic trioxide, radiation therapy TCF3 IKBKB 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy TCF3 IKBKB 1
ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine TCF3 EGLN3 1
atezolizumab, cabozantinib TCF3 RET 1
atezolizumab, tivozanib TCF3 KIT 1
atorvastatin, temozolomide, radiotherapy TCF3 NR1I3 1
atorvastatin, temozolomide, radiotherapy TCF3 HMGCR 1
avapritinib, midazolam TCF3 KIT 1
avastin, bortezomib TCF3 PSMB5 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab TCF3 HDAC3 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab TCF3 DNMT1 1
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment TCF3 KIT 1
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment TCF3 ABL1 1
bevacizumab, dasatinib, placebo TCF3 KIT 1
bevacizumab, dasatinib, placebo TCF3 ABL1 1
bevacizumab, temozolomide, vorinostat TCF3 HDAC3 1
binimetinib, hydroxychloroquine TCF3 MAP2K2 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib TCF3 KIT 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging TCF3 KIT 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging TCF3 RET 1
biopsy, biospecimen collection, crizotinib, radiologic examination TCF3 ALK 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography TCF3 KIT 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography TCF3 RET 1
bortezomib TCF3 PSMB5 1
bortezomib, gemcitabine hydrochloride TCF3 PSMB5 1
bortezomib, radiation therapy TCF3 PSMB5 1
bortezomib, temozolomide, pharmacological study TCF3 PSMB5 1
bosutinib TCF3 MAP2K2 1
botensilimab, balstilimab, chloroquine phosphate, celecoxib TCF3 CA3 1
bryostatin 1, paclitaxel TCF3 PRKCE 1
cabozantinib, atezolizumab, cabozantinib, cabozantinib TCF3 RET 1
cabozantinib, nivolumab TCF3 RET 1
cabozantinib, pembrolizumab TCF3 RET 1
capecitabine, vorinostat, radiotherapy, surgery to remove tumor TCF3 HDAC3 1
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy TCF3 CA3 1
celecoxib, cyclophosphamide, etoposide, thalidomide TCF3 CA3 1
celecoxib, isotretinoin, temozolomide, thalidomide TCF3 CA3 1
celecoxib, temozolomide, thalidomide, adjuvant therapy TCF3 CA3 1
ceritinib, cisplatin, gemcitabine hydrochloride, laboratory biomarker analysis, paclitaxel albumin-stabilized nanoparticle formulation, pharmacological study TCF3 ALK 1
cetuximab, bortezomib TCF3 PSMB5 1
chemotherapy, cladribine, radiation therapy TCF3 POLE3 1
cpt- 11, cisplatin, celecoxib, radiation, surgery TCF3 CA3 1
cyproheptadine hydrochloride, megestrol acetate TCF3 PGR 1
dabrafenib, trametinib TCF3 MAP2K2 1
dabrafenib, trametinib, carboplatin, vincristine TCF3 MAP2K2 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride TCF3 KIT 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride TCF3 ABL1 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method TCF3 KIT 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method TCF3 ABL1 1
dasatinib, laboratory biomarker analysis, physiologic testing TCF3 KIT 1
dasatinib, laboratory biomarker analysis, physiologic testing TCF3 ABL1 1
dasatinib, mfolfox6 TCF3 KIT 1
dasatinib, mfolfox6 TCF3 ABL1 1
dasatinib, pharmacological study TCF3 KIT 1
dasatinib, pharmacological study TCF3 ABL1 1
dasatinib, temozolomide, placebo, radiation therapy TCF3 KIT 1
dasatinib, temozolomide, placebo, radiation therapy TCF3 ABL1 1
decitabine, gemcitabine TCF3 DNMT1 1
disulfiram, copper, alkylating agents TCF3 AKR1A1 1
disulfiram, copper, alkylating agents TCF3 AHCY 1
disulfiram, copper, alkylating agents TCF3 HTT 1
e. coli cd-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis TCF3 DNMT1 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) TCF3 CHEK1 1
enzastaurin, lomustine TCF3 CHEK1 1
enzastaurin, temozolomide, radiation therapy TCF3 CHEK1 1
eras-007, encorafenib, cetuximab, palbociclib TCF3 LIMK2 1
erlotinib hydrochloride, selumetinib, laboratory biomarker analysis TCF3 MAP2K2 1
etomidate, midazolam, meperidine TCF3 GRIN2C 1
everolimus, sorafenib TCF3 KIT 1
everolimus, sorafenib TCF3 RET 1
flucytosine, polymerase chain reaction, immunohistochemistry staining method, gene therapy, pharmacological study, 3-tesla magnetic resonance imaging, laboratory biomarker analysis, therapeutic conventional surgery, e. coli cd-expressing genetically modified neural stem cells TCF3 DNMT1 1
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study TCF3 HDAC3 1
ft-2102, azacitidine, nivolumab, gemcitabine and cisplatin TCF3 DNMT1 1
gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy TCF3 IKBKB 1
gemcitabine, erlotinib, sorafenib TCF3 KIT 1
gemcitabine, erlotinib, sorafenib TCF3 RET 1
gemcitabine, oxaliplatin, imatinib TCF3 KIT 1
gemcitabine, oxaliplatin, imatinib TCF3 RET 1
gemcitabine, oxaliplatin, imatinib TCF3 ABL1 1
gemcitabine, placebo, sorafenib TCF3 KIT 1
gemcitabine, placebo, sorafenib TCF3 RET 1
gemcitabine, ribociclib, sonidegib, trametinib, filgrastim TCF3 MAP2K2 1
gemcitabine, sorafenib, radiotherapy TCF3 KIT 1
gemcitabine, sorafenib, radiotherapy TCF3 RET 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff TCF3 KIT 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff TCF3 HDAC3 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff TCF3 RET 1
gemcitabine, sunitinib TCF3 KIT 1
genistein, erlotinib hydrochloride, gemcitabine hydrochloride TCF3 ESRRA 1
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a TCF3 KIT 1
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a TCF3 RET 1
gsk2256098, trametinib TCF3 MAP2K2 1
h101, tislelizumab, lenvatinib TCF3 KIT 1
h101, tislelizumab, lenvatinib TCF3 RET 1
intestinal, multivisceral or modified multivisceral transplantation, alemtuzumab, tacrolimus, sirolimus TCF3 FKBP1A 1
ketoconazole TCF3 NR1I3 1
ko-2806, cabozantinib, adagrasib TCF3 RET 1
laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat TCF3 HDAC3 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil TCF3 KIT 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil TCF3 RET 1
lenvatinib, bevacizumab TCF3 KIT 1
lenvatinib, bevacizumab TCF3 RET 1
lenvatinib, pembrolizumab TCF3 KIT 1
lenvatinib, pembrolizumab TCF3 RET 1
lorlatinib, lorlatinib with chemotherapy1, lorlatinib with chemotherapy 2, lorlatinib post radiation TCF3 ALK 1
mebendazole TCF3 TUBA1A 1
mebendazole, vincristine, carboplatin, temozolomide, bevacizumab, irinotecan TCF3 TUBA1A 1
medical cannabis TCF3 HMGCR 1
nabiximols, temozolomide, nabiximols-matched placebo TCF3 HMGCR 1
nivolumab, cabozantinib TCF3 RET 1
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, ascorbic acid TCF3 EGLN3 1
paclitaxel, bryostatin 1 TCF3 PRKCE 1
paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) TCF3 KIT 1
paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) TCF3 RET 1
patupilone TCF3 TUBA1A 1
pazopanib, lapatinib TCF3 KIT 1
pegilodecakin, paclitaxel or docetaxel and carboplatin or cisplatin, folfox (oxaliplatin/leucovorin/5-fluorouracil), gemcitabine/nab-paclitaxel, capecitabine, pazopanib, pembrolizumab, paclitaxel, nivolumab, gemcitabine/carboplatin TCF3 KIT 1
pembrolizumab, azacitidine TCF3 DNMT1 1
pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel TCF3 KIT 1
pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel TCF3 RET 1
pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel TCF3 KIT 1
pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel TCF3 RET 1
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu TCF3 KIT 1
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu TCF3 RET 1
pembrolizumab, vorinostat, temozolomide, radiotherapy TCF3 HDAC3 1
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin TCF3 KIT 1
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin TCF3 RET 1
pexidartinib, durvalumab TCF3 KIT 1
ponatinib TCF3 KIT 1
ponatinib TCF3 RET 1
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery TCF3 RET 1
radiation therapy, temozolomide, sorafenib TCF3 KIT 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.